Things are certainly heating up with Sequenom. If we can get the overhang from the patent litigation out of the way, the stock price will rocket. Regardless of the litigation, the increases in sales are building nicely, and the MaterniT21 brand name is going to gain awareness and significant market share.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.